Study Finds Significant Differences in Access to New Alzheimer's Disease Treatments

Alzheimer's disease is a progressive neurological disorder associated with changes in memory, thinking, language, and everyday functioning. It is one of the major causes of dementia and can gradually reduce a person's ability to live independently. Newer disease-modifying medicines target amyloid-beta, a protein that accumulates in the brains of people with Alzheimer's disease. These medicines can slow cognitive decline in selected patients, but they do not cure the disease or restore all lost cognitive function. Treatment eligibility can depend on the stage of disease, confirmation of amyloid pathology, other medical conditions, medication risks, and the ability to undergo necessary monitoring. Some therapies require repeated infusions and brain imaging because of the risk of amyloid-related imaging abnormalities, which can include swelling or small areas of bleeding in the brain. Research led by Michigan Medicine examined treatment access using a database containing more than one million adults with mild cognitive impairment or dementia. Investigators identified 2,427 people who received anti-amyloid medication and compared them with a similar group who did not receive treatment. The study reported that Black adults had 86% lower odds and Hispanic adults had 79% lower odds of receiving these medicines than non-Hispanic white adults. Greater social and economic disadvantage was also associated with a lower likelihood of treatment. The researchers found that among patients who began treatment, initial medication adherence did not differ by race or ethnicity in the same way as treatment initiation. This suggests that barriers may occur during diagnosis, referral, eligibility assessment, or access to specialist treatment. The study does not establish that every observed difference results from discrimination or identify the precise cause of each treatment decision. Nevertheless, the findings highlight the need to investigate barriers to appropriate diagnosis and treatment. Medical significance: Equitable access to Alzheimer's care requires timely assessment, clear eligibility criteria, specialist availability, and informed discussions about benefits and risks. Patients and families should understand that these medicines can slow decline in selected cases but are not curative.